Matches in Nanopublications for { ?s ?p ?o <http://purl.org/np/RA9SaVBI5EOMPxLaIBR_I3Zc-iX-Eq_QzdkcGGswpg4m0#assertion>. }
Showing items 1 to 15 of
15
with 100 items per page.
- association type Statement assertion.
- cohort label "Children and adolescents" assertion.
- association label "Paliperidone is FDA-approved for schizophrenia aged 12-17. However, the pharmacologic portfolio, extrapolation from adult studies, and the long track record of the parent drug, risperidone in child/adolescent psychiatric (CAP) population might expand its therapeutic potential. An 8-week open-label study [9] examined paliperidone monotherapy for acute mania, mixed, or hypomanic episode in pediatric patients (n = 15, 6–17 years of age) with bipolar spectrum disorders. At the end of follow-up period, 11 subjects (73%) completed the study; treatment with paliperidone was associated with a 60% response rate (50% decrease in the Young Mania Rating Scale) and 40% remission (YMRS <12)" assertion.
- association subject DRUGBANK:DB01267 assertion.
- association predicate treats assertion.
- association object MONDO_0024612 assertion.
- association has_population_context cohort assertion.
- association relation OffLabelIndication assertion.
- MONDO_0024612 category Disease assertion.
- DRUGBANK:DB01267 category Drug assertion.
- cohort category Cohort assertion.
- cohort requiredMaxAge "17" assertion.
- cohort requiredMinAge "12" assertion.
- association publications 31096228 assertion.
- association provided_by NeuroDKG assertion.